AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05093439 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Heart Rate Variability
Description: Heart rate variability wil be calculated from patients' 10 sec ECG with a dedicated software (Kubios).
Study NCT05942365 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZSP1273
Description: Drug Warfarin oral Drug midazolam oral
Study NCT04970277 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: drinking water group
Description: Those randomized to drink water group were asked to drink 200 mL colorless water every 10 minutes, starting at the time of capsule ingestion until three times in total.
Study NCT04970277 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: control group
Description: Those randomized to control group were asked not to drink extra water after capsule ingestion.
Study NCT06444230 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Routine Physical therapy with Neurodevelopmental technique
Description: participants will recieve a session of 40 minutes including routine physical therapy along with the neurodevelopmental technique for 3 times a week for 12 weeks
Study NCT06444230 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Routine Physical therapy
Description: participants will recieve a session of 40 minutes including, stretching, neck and trunk stabilization and strengthening exercise followed by a warm up and cool down for 3 times a week for 12 weeks follo
Study NCT05535504 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Low-frequency rTMS (experimental)
Description: Frequency: Low-frequency (1Hz) rTMS / Intensity: 100% of resting motor threshold / Location: motor hotspot of the contralesional primary motor cortex (the first dorsal interosseous muscle) / Number of total stimuli : 1800 ; Coil orientation: tangential to scalp
Study NCT05535504 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Low-frequency rTMS (sham comparator)
Description: Frequency: Low-frequency (1Hz) rTMS / Intensity: 100% of resting motor threshold / motor hotspot of the contralesional primary motor cortex (the first dorsal interosseous muscle) / Number of total stimuli : 1800 ; Coil orientation: vertical to scalp
Study NCT05295212 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Pemetrexed (500mg/m2)/Paclitaxel (260mg/m2) Carboplatin (AUC=4-5) Atezolizumab(1200mg) ivgtt, every 21 days Range from 4 cycles
Study NCT05829070 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CHAT-S
Description: The CHAT-S intervention will include 4 videoconference sessions over a 2-month time period that is delivered by a patient navigator. Session 1 will include content to educate participants about survivorship care and common types of follow-up care required for their specific cancer, as well as, basic insurance terms and concepts. Session 2 will teach participants about their own insurance plan (e.g., coverage, benefits, breakdown of bills, and explanation of benefits) so they can better navigate both the medical and insurance systems. Session 3 reviews health insurance laws (e.g., ACA, FMLA, No Surprises Act) and how to proceed with an appeals process. Session 4 explains how to manage the costs through budgeting and cost-of-care conversations with their medical providers.
Study NCT05829070 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Usual Care
Description: Usual care will consist of a resource list that describes organizational and community resources available on insurance, financial burden, and survivorship care. Further, we will track whether participants were referred or engaged in services using the follow-up surveys and via the EHR/claims data.
Study NCT06372626 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ZG005
Description: ZG005 for dose escalations are set as 10mg/kg, 20mg/kg, and the other doses after discussion. intravenous infusion, once every 3 weeks.~ZG005 for dose expansion will commence after the Recommended Phase 2 Dose (RP2D) is determined during the dose-escalation stage.
Study NCT06372626 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: IV infusion
Study NCT06372626 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: IV infusion
Study NCT06372626 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 0.9% Sodium Chloride Injection
Study NCT04940000 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Patient managed at the IUCT-O and by a private speech therapist (near the patient's home).
Description: Each patient included will have a video-assisted remote speech therapy consultation with a private speech therapist (near the patient's home) and the expert speech therapist of IUCT-O center.~At the end of this video consultation, the patient and the private speech therapist will be asked to complete a satisfaction questionnaire.
Study NCT05368467 — intervention group
Intervention type: COMBINATION_PRODUCT
Intervention: The clinical course and disease management
Description: The clinical course and disease management of pulmonary hypertension patients
Study NCT04541589 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CFZ533 (iscalimab)
Description: Biological
Study NCT04541589 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: CFZ533 Placebo
Description: Matching placebo
Study NCT05224271 — intervention group
Intervention type: OTHER
Intervention: Electronic Health Record Review
Description: Medical records are collected
Study NCT05224271 — intervention group
Intervention type: OTHER
Intervention: Medical Device Usage and Evaluation
Description: Fitbit information is collected
Study NCT05224271 — intervention group
Intervention type: OTHER
Intervention: Survey Administration
Description: Complete surveys
Study NCT05935553 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Baclofen 30 mg
Description: * baclofen 10 mg capsule (for the 30 mg-baclofen 30 mg arm)~* Dosage: 3 capsules of baclofen 10 mg per day~* route of administration: Oral~* duration of treatment: Total duration of treatment is 13 weeks including 1 week of dose escalation, 11 weeks of maintenance at full dose, and 1 week of dose de-escalation
Study NCT05935553 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Baclofen 60 mg
Description: * baclofen 20 mg capsule (for the 60 mg baclofen arm)~* Dosage: 3 capsules of baclofen 20 mg per day~* route of administration: Oral~* duration of treatment: Total duration of treatment is 13 weeks including 1 week of dose escalation, 11 weeks of maintenance at full dose, and 1 week of dose de-escalation
Study NCT05935553 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: * placebo capsule (for the placebo arm)~* Dosage:3 capsules of placebo per day~* route of administration: Oral~* duration of treatment: Total duration of treatment is 13 weeks including 1 week of dose escalation, 11 weeks of maintenance at full dose, and 1 week of dose de-escalation
Study NCT06585878 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Ablative Radiotherapy (SABR)
Description: Without altering the patients' systemic treatment plans, patients who meet the inclusion criteria after MDT discussion will receive SBRT radiotherapy for all lesions/all metastatic lesions based on the guideline-recommended medications. The radiotherapy plan is based on the SABR-COMET protocol and Timmerman's constraints.
Study NCT06676657 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: iPancreas automated insulin delivery system
Description: The Model Predictive Control (MPC) insulin infusion algorithm contains a model within the controller that takes as an input the aerobic metabolic expenditure in addition to the CGM and meal in puts. The algorithm uses heart rate and accelerometer data collected on the patient's body to calculate metabolic expenditure (METs). The METs then acts on the model for the insulin dynamics, whereby more energy expenditure and longer duration exercise can lead to a more substantial effect of insulin on the CGM. The MPC also has missed meal insulin bolus detection where the system will calculate the amount of insulin that was missed for a meal. The missed meal boluses can be delivered automatically without any input from the user. This feature can also be disabled. The MPC has a new feature called hyperglycemia pattern detection and dosing algorithm that will analyze problem patterns associated with high blood sugar and automatically calculate and deliver a correction dose.
Study NCT03827434 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Continuous glucose Monitoring Devices and Clarity Software
Description: Patients with DM2 at the intervention group will be managed by Continuous glucose Monitoring and Clarity software
Study NCT03827434 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Point of Care (POC) blood glucose
Description: Testing Blood Glucose levels with Point of Care (POC) blood glucose
Study NCT06706531 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Standard treatment
Description: All participants received up to six treatment sessions at a frequency of twice per week over a 3-week period i.e. ultrasound (0.5 W/cm² of 3 MHz for 5 minutes over plantar aspect of foot), stretching exercises and strengthening exercises. The exercise pro
Study NCT06706531 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard treatment
Description: All participants received up to six treatment sessions at a frequency of twice per week over a 3-week period i.e. ultrasound (0.5 W/cm² of 3 MHz for 5 minutes over plantar aspect of foot), stretching exercises and strengthening exercises. The exercise pro
Study NCT06706531 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Sham Dry needling
Description: The sham dry needling group will also receive 6 sessions of sham dry needling on soleus, quadratus plantae, flexor digitorum brevis, and abductor halluces muscles for 5 minutes.Sterilized disposable stainless steel acupuncture needles of 0.25mm x 30mm will be used with depth of 20-55mm.The plantar and medial surface of the foot and ankle will be cleaned with alcohol. The sham dry needling will be performed for 5 minutes.
Study NCT06706531 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Dry needling
Description: The dry needling group will receive 6 sessions of dry needling using a standardized trigger point protocol on soleus, quadratus plantae, flexor digitorum brevis, and abductor halluces muscles for 5 minutes. Sterilized disposable stainless steel acupuncture needles of 0.25mm x 30mm will be used with depth of 20-55mm. The calf, plantar and medial surface of the foot and ankle will be cleaned with alcohol. Following insertion, needles will be manipulated bi-directionally to elicit a sensation of aching, tingling, deep pressure, heaviness or warmth. The needles will then left in situ for 5 minutes.
Study NCT05835505 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BRS201
Description: Groups 1, 2, 3, and 4 will all contain 7 subjects each, with each subject receiving active study drug and placebo in a randomized order; half will receive the placebo first for four weeks followed by active treatment for four weeks, while the other half will receive active treatment for four weeks followed by placebo for four weeks.
Study NCT05835505 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Groups 1, 2, 3, and 4 will all contain 7 subjects each, with each subject receiving active study drug and placebo in a randomized order; half will receive the placebo first for four weeks followed by active treatment for four weeks, while the other half will receive active treatment for four weeks followed by placebo for four weeks.
Study NCT06123377 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Angiogenic factor
Description: sFLt-1/PGIF below or equal to 33
Study NCT06123377 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Angiogenic factor
Description: sFLt-1/PGIF below or equal to 33
Study NCT04481243 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pneumovax 23- pneumococcal polysaccharide
Description: PPSV23 is a vaccine to help protect against serious infection due to the Streptococcus pneumoniae bacteria. One dose administered intramuscularly or subcutaneously.
Study NCT04481243 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood draw
Description: 6 ml blood draw at baseline and 6 months post immunization
Study NCT06215534 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: first reference product series 1
Description: dextrose (containing 25 grams of carbohydrates)
Study NCT06215534 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: second reference product seies 1
Description: dextrose (containing 25 grams of carbohydrates)
Study NCT06215534 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: third reference product series 1
Description: dextrose (containing 25 grams of carbohydrates)
Study NCT06215534 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: first concept product series 1
Description: Standard tube feed (containing 25 grams of carbohydrates)
Study NCT06215534 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: second concept product series 1
Description: Tube feed with added fibers (containing 25 grams of carbohydrates)
Study NCT06215534 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: third concept product series 1
Description: Tube feed with extra energy (containing 25 grams of carbohydrates)
Study NCT06215534 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: 4th concept product seris 1
Description: Tube feed with extra energy and added fibers (containing 25 grams of carbohydrates)
Study NCT06215534 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: 5th concept product series 1
Description: Plant based oral nutritional supplement for disease related malnutrition (containing 25 grams of carbohydrates
Study NCT06215534 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: 6th concept product series 1
Description: Oral nutritional supplement for disease related malnutrition in patients with malabsorption and/or maldigestion (containing 25 grams of carbohydrates
Study NCT06215534 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: 1st reference product series 2
Description: dextrose (containing 25 grams of carbohydrates)
Study NCT06215534 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: 2nd reference product series 2
Description: dextrose (containing 25 grams of carbohydrates)
Study NCT06215534 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: 3rd reference product series 2
Description: dextrose (containing 25 grams of carbohydrates)
Study NCT06215534 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: 1st concept product series 2
Description: High energy plant based tube feed (containing 25 grams of carbohydrates)
Study NCT06215534 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: 2nd concept product series 2
Description: High energy plant based tube feed with added fibers (containing 25 grams of carbohydrates)
Study NCT06215534 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: 3rd concept product series 2
Description: High protein tube feed (containing 25 grams of carbohydrates)
Study NCT06215534 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: 4th concept product series 2
Description: High protein, high energy tube feed based on peptides (containing 25 grams of carbohydrates)
Study NCT06215534 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: 5th concept product series 2
Description: Oral nutritional supplement for disease related malnutrition in patients with muscle loss (containing 25 grams of carbohydrates)
Study NCT06215534 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: 6th concept product series 2
Description: Oral nutritional supplement for disease related malnutrition (containing 25 grams of carbohydrates)
Study NCT05872685 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S1
Description: S-1 orally intake as perioperative chemotherapy
Study NCT05872685 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: S1
Description: S-1 orally intake as perioperative chemotherapy
Study NCT05872685 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Oxaliplatin (130 mg/m2) infusion as perioperative chemotherapy
Study NCT05872685 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxaliplatin
Description: Oxaliplatin (130 mg/m2) infusion as perioperative chemotherapy
Study NCT05872685 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Serplulimab
Description: Perioperative serplulimab, 300 mg IV infusion
Study NCT05872685 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Perioperative placebo, 300 mg IV infusion
Study NCT04633668 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CBT for parasomnias (CBT-p)
Description: Psychoeducation, sleep hygiene, imagery re-scripting, scheduled awakenings, safety planning, cognitive therapy, and stress management for 6 weeks
Study NCT04633668 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Self-Monitoring
Description: Monitoring of sleep quality through sleep diary, actigraphy, nightmare experiences for 6 weeks
Study NCT05314868 — intervention group
Intervention type: DEVICE
Intervention: PhotoFix
Description: Surgical repair with patch.
Study NCT04985929 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sildenafil 50 mg
Description: Sildenafil is a phosphodiesterase type-5 inhibitor, which augments/prolongs the naturally occurring nitric oxide mediated vasodilatory pathway. Sildenafil pill is over-encapsulated to be identical in appearance to the placebo intervention.
Study NCT04985929 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Medical-grade placebo pill, over-encapsulated to be identical in appearance to the sildenafil intervention.
Study NCT04839510 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MRG002
Description: Administrated intravenously
Study NCT05717361 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ketamine-lidocaine
Description: In the KL group, patients will be administered in a total volume of 20 mL,1mL/10 kg of the solution containing ketamine, lidocaine at predefined concentrations.~As maintenance, they will be receiving 1mL/10kg/h of the aforementioned solution
Study NCT05717361 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Remifentanil
Description: In the Remifentanil group, patients will be administered in a total volume of 20 mL, 2 mcg/kg of fentanyl. As maintenance, they will be receiving 1 mL/10kg/h of a remifentanil solution
Study NCT05587816 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Validation of the PortionSize app
Description: The investigators will recruit 40 dyads (40 children aged 7-12 years old and 40 parents or caregivers) using a convenience sample for this pilot study. Children and their parents or caregivers will be trained to use the PortionSize app at Pennington Biomedical Research Center (PBRC). Children will use the PortionSize app and estimate food intake from pre-weighed meals (simulated meals) at PBRC clinic. Children will not consume the simulated meals. Children's parents or caregivers will also use the PortionSize app and estimate the food intake of their children (at least one meal and a snack each day) for two consecutive days at home.
Study NCT04715113 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Normobaric hypoxia (FiO2 15%)
Description: Inhalation of deoxygenated air through an altitude simulator (Altitrainer), for approx. 1/2 hour given by a facemask, first at rest and then during exercise.
Study NCT04715113 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Placebo-ambient air (FiO2 21%)
Description: Inhalation of room air through an altitude simulator (Altitrainer), for approx. 1/2 hour given by a facemask, first at rest and then during exercise.
Study NCT04715113 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Normobaric hypoxia (FiO2 15%) under Sildenafil
Description: Inhalation of deoxygenated air through an altitude simulator (Altitrainer), for approx. 1/2 hour given by a facemask, first at rest and then during exercise under Sildenafil.
Study NCT04715113 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo-ambient air (FiO2 21%) under Sildenafil
Description: Inhalation of room air through an altitude simulator (Altitrainer), for approx. 1/2 hour given by a facemask, first at rest and then during exercise under Sildenafil.
Study NCT04634097 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental group
Description: Clusters will be proposed LE DECLIC EPRI intervention, which is a complex intervention, associating 3 components,:~A. DECLIC program set up in the centers, open to concerned patients.~B. 3 training sessions :~* one public of primary care physicians in order to give them the opportunity to be involved in the medical care in charge of the patient suffering from cancer pain.~* one public of cancer physicians, leaders of opinions in each cancer centers participating to the study and one public of health professionals in order to train them to be educators (team building).~* for healthcare professionals in order to train them as educators in this program.~C. The collaboration of one primary care network, specialized in pain management, in order to reinforce the patient care pathway.
Study NCT04634097 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: standrad group
Description: Standard follow-up patient related to pain. Specific to each center : with or without existing local ETP program (standard care).